PURPOSE: To prospectively assess the long-term @entity137 of brachytherapy in female survivors with localized genital tract @entity5 . @entity1 AND METHODS: The data concerning 42 @entity1 treated at Gustave Roussy between 1971 and 2004, were both retrospectively and prospectively analyzed. Strictly confidential constructed surveys based on the LENT SOMA/SF-36v2 questionnaires were mailed and 51% were completed. Complications were recorded throughout the follow-up period and graded according to CTCAE, version 4.0. RESULTS: The median age at diagnosis was 1.7years (range, 0.6-16.6) and most @entity1 (69%) had @entity980 . Treatments included brachytherapy delivered in all @entity1 , chemotherapy (88%), surgery (31%), and external beam radiotherapy (5%). At a median follow-up of 15.5years, 41/42 @entity1 were alive. A total of 160 late effects were identified in 32/42 (76%) @entity1 : 72% G1-2, and 28% G3-4 (the mean number of all grade late effects per @entity1 : 4 [median: 2.5; range, 0-16] and the mean number of G3-4 late effects per @entity1 : 1[median: 0; range, 0-8]). The most common all grade late @entity137 were gynecological (75/160; 47%) and G3-4 were urinary (24/45; 53%). Sixteen @entity1 (38%) required surgical treatment of late complications. The 15-year actuarial incidence rate of G3-4 late effects was 51%. The total number of all grade and G3-4 late effects was significantly increased in @entity1 treated before 1990 (p=0.005 and p=0.008), when the cumulative dose was higher (p=0.03 and p=0.02), when the maximal dose was delivered to the ovaries (p=0.002 and p=0.04), and when the brachytherapy volume was larger (p=0.03 and p=0.02). Quality of life was good or very good in 91% of @entity1 who completed the surveys. CONCLUSION: Long-term effects decreased with advances in treatment. Stringently controlled brachytherapy parameters should allow us to pursue improvements in order to prevent or minimize long-term sequelae.

Late @entity137 of brachytherapy after female genital tract XXXX treated during childhood: Prospective evaluation with a long-term follow-up.

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity980 :: ('MESH:D012208', 'Disease') :: ['rhabdomyosarcomas']
@entity5 :: (MESH:D009369,Disease) :: ['tumors']
